Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lilly launches smaller insulin vial for diabetes patients

Lilly launches smaller insulin vial for diabetes patients

9th December 2009

Lilly has introduced a smaller insulin vial to the pharmaceutical market, which is indicated as a therapy for diabetes patients who are being treated in hospitals.

The new product comes in the format of a 3 ml dose (300 units) and is designed to be used alongside Lilly’s exisiting Humalog (insulin lispro injection [rDNA origin]) and Humulin R-U100 (regular insulin human injection, USP [rDNA origin]) products.

With the release of the smaller insulin vials, the firm aims to offer hospitals more flexibility when evaluating their storage, delivery and distribution methods for the treatment.

Matt Beebe, insulin brand team leader at Lilly, stated: “Partnering with our institutional customers, we believe hospitals will find it to be a valuable option when evaluating their insulin storage, delivery and distribution needs.”

In other Lilly news, this week the firm announced that its therapy Zyprexa (olanzapine) has been indicated for two different treatment options in adolescent patients.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.